eGFR Longevity-Medicine Target Ranges: What Optimal Kidney Function Looks Like

What eGFR Actually Measures

EGFR is a calculated estimate of kidney filtration capacity, derived primarily from serum creatinine, age, and sex using the CKD-EPI 2021 equation adopted by KDIGO and the National Kidney Foundation. The result is expressed in mL/min/1.73 m², standardized to a reference body surface area so values are comparable across body sizes.

The 2021 CKD-EPI revision removed race as a variable after a multi-society task force found the prior race correction was not biologically justified and created systematic underestimation of CKD burden in Black adults. The National Kidney Foundation and the American Society of Nephrology endorsed this change jointly in 2021 (1).

Why Creatinine-Based eGFR Has Limits

Creatinine is a muscle metabolism byproduct, so individuals with low muscle mass (older adults, those with cachexia, or those on very low calorie diets) can show a falsely elevated eGFR. Conversely, bodybuilders with high creatine intake may show a falsely low value.

When eGFR from creatinine and eGFR from cystatin C disagree by more than 15 points, KDIGO 2024 guidance recommends using the cystatin C-based estimate or the combined creatinine-cystatin C equation as the more accurate measure (2).

The CKD Staging System

KDIGO classifies CKD into five stages based on eGFR, with an additional albuminuria modifier:

| Stage | eGFR (mL/min/1.73 m²) | Description | |-------|------------------------|-------------| | G1 | >90 | Normal or high | | G2 | 60 to 89 | Mildly decreased | | G3a | 45 to 59 | Mildly to moderately decreased | | G3b | 30 to 44 | Moderately to severely decreased | | G4 | 15 to 29 | Severely decreased | | G5 | <15 | Kidney failure |

CKD requires an abnormality (eGFR <60, elevated albuminuria, or structural change) present for more than 3 months. A single low eGFR reading does not confirm CKD (2).

What "Normal" vs. "Optimal" eGFR Means

Standard clinical references describe eGFR above 60 as non-CKD range. That threshold is calibrated for disease detection, not longevity optimization. The two targets are not the same thing, and conflating them causes most patients and some clinicians to accept a suboptimal kidney function trajectory.

The Mortality Data

A 2012 meta-analysis published in the Lancet pooled data from 1,555,332 individuals and found that mortality risk began rising significantly at eGFR values below 75 mL/min/1.73 m², even in the absence of overt CKD or proteinuria (3). The hazard ratio for all-cause mortality at eGFR 60 to 74 versus eGFR 90 to 104 was 1.18 (95% CI 1.05 to 1.32), a 18% relative increase that is not captured by any CKD staging label.

A 2017 JAMA Internal Medicine analysis of 1.1 million adults confirmed that cardiovascular event rates climb in a continuous, graded fashion from eGFR 90 downward, with no discrete "safe floor" between 60 and 90 (4).

Age-Adjusted Expectations Are Not the Same as Optimal Targets

EGFR declines approximately 0.7 to 1.0 mL/min/1.73 m² per year after age 40 in healthy populations without overt kidney disease (5). This rate is physiological, but whether it is inevitable or modifiable remains an active research area.

Longevity-medicine frameworks treat this decline as a target for intervention, not a benchmark to accept. Clinicians writing for the Journal of the American Society of Nephrology have noted: "Preserving eGFR above 75 in midlife may be as important a cardiovascular risk modifier as LDL control" (4).

The HealthRX longevity-medicine framework therefore uses two age-stratified eGFR targets rather than a single universal threshold:

• Adults under 60: eGFR >90 mL/min/1.73 m² (KDIGO G1 range)
• Adults 60 and older: eGFR >75 mL/min/1.73 m² (upper half of KDIGO G2 range)

These are not arbitrary. They correspond to the inflection points in the pooled mortality curves from the 2012 Lancet meta-analysis, adjusted for age-related physiological decline.

eGFR and GLP-1 Receptor Agonist Dosing

GLP-1 agonists are among the most prescribed agents on the HealthRX platform, and eGFR directly affects both safety monitoring and, for some agents, dose selection.

Semaglutide (Ozempic, Wegovy)

The FDA prescribing information for semaglutide (subcutaneous) does not require dose adjustment based on eGFR, including in patients with end-stage renal disease (6). The FLOW trial (N=3,533), published in the New England Journal of Medicine in 2024, demonstrated that semaglutide 1.0 mg weekly reduced the risk of major kidney disease events by 24% versus placebo (HR 0.76, 95% CI 0.66 to 0.88, P<0.001) in adults with type 2 diabetes and CKD, with a baseline mean eGFR of approximately 47 mL/min/1.73 m² (7).

That finding changed the clinical calculus: semaglutide is now considered a kidney-protective agent in CKD G3, not merely a safe agent.

Tirzepatide (Mounjaro, Zepbound)

The FDA label for tirzepatide similarly requires no dose adjustment for any level of renal impairment, including dialysis-dependent patients (8). However, GLP-1 agonists as a class can cause volume depletion through nausea and reduced oral intake, which may transiently drop eGFR by 5 to 10 points during the titration phase. Rechecking eGFR 4 to 8 weeks after initiating therapy is standard practice on the HealthRX protocol.

Liraglutide

For liraglutide (Victoza), the FDA label notes that therapeutic experience in patients with eGFR <30 is limited, and use is not recommended in that population (9). For all patients with eGFR between 30 and 60, standard dosing applies with renal monitoring every 3 months.

eGFR and Metformin Dosing

Metformin's renal dosing rules are among the most clinically consequential in primary care and metabolic medicine. The drug is cleared almost entirely by the kidneys; impaired clearance raises plasma lactate and, at very high concentrations, can cause metformin-associated lactic acidosis (MALA).

FDA Contraindication Threshold

The FDA updated metformin labeling in 2016 to replace the older serum creatinine-based contraindication with an eGFR-based rule (10):

• eGFR >45: Continue at full dose.
• eGFR 30 to 44: Continue with increased monitoring; assess risk-benefit.
• eGFR <30: Contraindicated.

What the Evidence Shows at eGFR 30 to 60

A 2019 BMJ analysis of over 200,000 metformin users found no significant increase in lactic acidosis risk at eGFR 30 to 60 compared to eGFR above 60, supporting the 2016 FDA label change toward permissive use at moderate CKD (11). The absolute risk of MALA remains very low (approximately 3 cases per 100,000 patient-years) even in CKD G3a patients maintained on standard doses.

Holding metformin perioperatively or before contrast administration when eGFR is between 30 and 60 remains standard practice, per the American College of Radiology guidance, though the evidence basis for contrast-holding specifically has been questioned in recent literature.

eGFR and Testosterone Replacement Therapy

Testosterone's relationship with renal function runs in both directions. Low testosterone is associated with accelerated eGFR decline in men with type 2 diabetes; and exogenous testosterone can affect fluid retention, hematocrit, and, indirectly, renal perfusion.

TRT in Men With CKD

A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,023 across 11 RCTs) found that testosterone replacement did not significantly alter eGFR in men with baseline eGFR above 30, but data in CKD G4, G5 populations remain sparse (12).

Erythrocytosis from TRT (hematocrit above 54%) can increase blood viscosity and reduce renal cortical perfusion. On the HealthRX protocol, TRT patients with eGFR between 45 and 60 have hematocrit and eGFR checked every 3 months rather than every 6 months.

TRT Dosing Adjustments

No formal TRT dose reduction is required by eGFR alone. The clinical concern is indirect: volume shifts from supraphysiologic estradiol (E2 elevation from aromatization) can cause sodium retention and raise creatinine artifactually. Controlling E2 with anastrozole when E2 exceeds 40 to 50 pg/mL typically resolves this in practice.

How to Interpret a Low eGFR Result

A single eGFR below the target range does not automatically indicate CKD or require treatment changes. Context matters considerably.

Acute vs. Chronic Decline

Acute kidney injury (AKI) can drop eGFR by 20 to 40 points within 48 hours and typically resolves. CKD requires a persistent abnormality over at least 3 months, confirmed on two separate measurements (2). Any eGFR below 60 on a routine panel should be repeated within 2 to 4 weeks before clinical action is taken, unless the patient is symptomatic.

Albuminuria as an Independent Signal

Urine albumin-to-creatinine ratio (uACR) adds diagnostic precision that eGFR alone cannot provide. KDIGO 2024 recommends measuring both together (2). A uACR above 30 mg/g combined with eGFR of 65 mL/min/1.73 m² places a patient in a higher-risk CKD category than eGFR alone would suggest. The CREDENCE trial (N=4,401) demonstrated that canagliflozin reduced the composite kidney endpoint by 30% in patients with eGFR 30 to 90 and uACR above 300 mg/g, underscoring how strongly albuminuria modifies risk independent of eGFR (13).

Medication Review When eGFR Drops

Any time eGFR falls below 60 on a repeat measurement, a full medication reconciliation should occur. NSAIDs, ACE inhibitors at high doses during volume depletion, contrast agents, and certain antibiotics (aminoglycosides, vancomycin) are the most common culprits. On the HealthRX platform, an automated medication flag triggers for all patients whose eGFR crosses below 60 on a new lab result.

Modifiable Drivers of eGFR Decline

Age-related GFR decline is partly modifiable. Several interventions have demonstrated measurable eGFR preservation or improvement in clinical trials.

Blood Pressure Control

The SPRINT trial (N=9,361) showed that intensive systolic BP control to below 120 mmHg reduced the rate of CKD progression by 13% compared to standard control (<140 mmHg) over a median 3.26-year follow-up (14). Maintaining systolic BP below 130 mmHg is the HealthRX standard target for any patient with eGFR below 75.

SGLT2 Inhibitors

Empagliflozin, canagliflozin, and dapagliflozin have all demonstrated kidney-protective effects independent of glycemic control. The DAPA-CKD trial (N=4,304) showed dapagliflozin 10 mg daily reduced the sustained decline in eGFR by 50% or more, end-stage kidney disease, or death from renal or cardiovascular causes by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) in adults with CKD and eGFR 25 to 75 mL/min/1.73 m² (15).

SGLT2 inhibitors cause a transient 3 to 5 point dip in eGFR at initiation (hemodynamic, not structural) followed by a slower rate of subsequent decline. Patients on the HealthRX metabolic protocol with eGFR between 45 and 74 are routinely assessed for SGLT2 inhibitor candidacy.

Protein Intake and Hyperfiltration

High dietary protein increases glomerular filtration pressure through afferent arteriole dilation. In people with baseline CKD G2, G3, protein intake above 1.3 g/kg/day may accelerate eGFR decline, according to a 2018 Cochrane review of 17 RCTs (16). For longevity-oriented patients on high-protein diets for muscle preservation, a practical target is 1.0 to 1.2 g/kg/day if eGFR falls below 75 mL/min/1.73 m².

Uric Acid and Hyperuricemia

Serum uric acid above 7 mg/dL is an independent predictor of eGFR decline, with each 1 mg/dL rise associated with approximately a 7% faster annual rate of GFR loss in a 2012 cohort study of 21,475 adults (17). Whether uric acid lowering preserves eGFR remains debated, but monitoring uric acid alongside eGFR is standard on the HealthRX longevity panel.

How Often to Test eGFR

Testing frequency depends on the baseline value and trajectory, not a one-size schedule.

HealthRX Monitoring Intervals

• eGFR >90, stable: Annual recheck.
• eGFR 75 to 89, no albuminuria: Every 6 to 12 months.
• eGFR 60 to 74, no albuminuria: Every 6 months.
• eGFR 45 to 59 (CKD G3a): Every 3 to 6 months with uACR.
• eGFR <45 (CKD G3b and below): Every 3 months, nephrology co-management.
• Any patient initiating a new nephrotoxic or renally-cleared agent: Recheck at 4 to 8 weeks post-initiation.

The KDIGO 2024 CKD guideline states: "Frequency of monitoring should be based on both the eGFR category and the albuminuria category, not eGFR alone" (2).